29 results
F-3
SCNI
Scinai Immunotherapeutics Ltd
30 Jan 24
Shelf registration (foreign)
4:19pm
, the Company performed a turnaround process that included raising fresh capital, hiring new talent (including a new CEO), signing a research collaboration
424B3
SCNI
Scinai Immunotherapeutics Ltd
2 Jan 24
Prospectus supplement
8:24am
that M-001 did not meet its clinical endpoints, the Company performed a turnaround process that included raising fresh capital, hiring new talent
F-1/A
SCNI
Scinai Immunotherapeutics Ltd
22 Dec 23
Registration statement (foreign) (amended)
9:11am
capital, hiring new talent (including a new CEO), signing a research collaboration agreement with and in-licensing new intellectual property from world
F-1
SCNI
Scinai Immunotherapeutics Ltd
30 Oct 23
Registration statement (foreign)
4:59pm
2020, indicating that M-001 did not meet its clinical endpoints, the Company performed a turnaround process that included raising fresh capital, hiring
424B5
SCNI
Scinai Immunotherapeutics Ltd
19 Sep 23
Prospectus supplement for primary offering
10:03am
endpoints, the Company performed a turnaround process that included raising fresh capital, hiring new talent (including a new CEO), signing a research … 2020, indicating that M-001 did not meet its clinical endpoints, the Company performed a turnaround process that included raising fresh capital, hiring
424B2
ak60z1jcliyx kn3j
28 Aug 23
Prospectus for primary offering
4:01pm
F-3
rjovbsjs2bmjn2a71nt
18 Aug 23
Shelf registration (foreign)
4:16pm
10-K
tta v05ebe
17 Apr 23
Annual report
4:06pm
6-K
EX-99.1
jnzpy5r36psqo
13 May 22
Report of Foreign Private Issuer
7:48am
424B5
vhq 3m6wb67
28 Dec 21
Prospectus supplement for primary offering
5:20pm
424B5
nuakgd1
27 Dec 21
Prospectus supplement for primary offering
6:22am
6-K
EX-99.1
s2i0z1rkhs3n3ptc
4 Mar 21
Report of Foreign Private Issuer
1:01pm
424B5
auif3
1 Feb 21
Prospectus supplement for primary offering
5:08pm
424B5
ye72yhnhnxu0m6
29 Jan 21
Prospectus supplement for primary offering
12:00am
6-K
EX-99.3
6hr5uj2u n8
2 Oct 20
Condensed Interim Financial Statements
12:00am
424B5
hwrk79sushbh 13u94es
2 Oct 20
Prospectus supplement for primary offering
12:00am
POS AM
wxfkdv4l us
7 Jan 20
Prospectus update (post-effective amendment)
10:51am